Atorvastatin and ischemic stroke: Mechanisms and therapeutic applications.

IF 3.3 3区 医学 Q2 CLINICAL NEUROLOGY
Peyman Esmaili-Shahzade-Ali-Akbari, Abolfazl Azami Tameh, Houman Parsaei, Shirin Barati, Zeinab Vahidinia
{"title":"Atorvastatin and ischemic stroke: Mechanisms and therapeutic applications.","authors":"Peyman Esmaili-Shahzade-Ali-Akbari, Abolfazl Azami Tameh, Houman Parsaei, Shirin Barati, Zeinab Vahidinia","doi":"10.1093/jnen/nlag009","DOIUrl":null,"url":null,"abstract":"<p><p>Stroke is a leading cause of death and disability, affecting approximately 13.7 million people worldwide and causing 5.5 million deaths annually. Effective treatment options for ischemic stroke are still limited and existing clinical interventions have limitations such as the time window for treatment. Therefore, research is needed to find complementary therapies that can reduce the complications of stroke or prevent its occurrence. Atorvastatin is an oral medication used to lower lipid levels via competitive inhibition of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, which results in decreased cholesterol production. Much evidence demonstrates the effectiveness of atorvastatin in stroke but few studies have specifically examined its neuroprotective effects and the underlying mechanisms. This review focuses on the neuroprotective actions of atorvastatin in preclinical and clinical studies and provides an updated discussion on molecular mechanisms contributing to these possible effects in ischemic stroke. We hope that this review will help readers gain a better understanding of the roles of atorvastatin in cerebral ischemic stroke and provide more comprehensive insights for basic research and novel strategies for the treatment of patients with stroke.</p>","PeriodicalId":16682,"journal":{"name":"Journal of Neuropathology and Experimental Neurology","volume":" ","pages":"815-830"},"PeriodicalIF":3.3000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuropathology and Experimental Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jnen/nlag009","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Stroke is a leading cause of death and disability, affecting approximately 13.7 million people worldwide and causing 5.5 million deaths annually. Effective treatment options for ischemic stroke are still limited and existing clinical interventions have limitations such as the time window for treatment. Therefore, research is needed to find complementary therapies that can reduce the complications of stroke or prevent its occurrence. Atorvastatin is an oral medication used to lower lipid levels via competitive inhibition of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, which results in decreased cholesterol production. Much evidence demonstrates the effectiveness of atorvastatin in stroke but few studies have specifically examined its neuroprotective effects and the underlying mechanisms. This review focuses on the neuroprotective actions of atorvastatin in preclinical and clinical studies and provides an updated discussion on molecular mechanisms contributing to these possible effects in ischemic stroke. We hope that this review will help readers gain a better understanding of the roles of atorvastatin in cerebral ischemic stroke and provide more comprehensive insights for basic research and novel strategies for the treatment of patients with stroke.

阿托伐他汀和缺血性中风:机制和治疗应用。
中风是造成死亡和残疾的主要原因,每年影响全世界约1 370万人,造成550万人死亡。缺血性脑卒中的有效治疗方案仍然有限,现有的临床干预措施也有局限性,如治疗的时间窗口。因此,需要研究找到能够减少中风并发症或预防其发生的补充疗法。阿托伐他汀是一种口服药物,通过竞争性抑制3-羟基-3-甲基戊二酰辅酶a (HMG-CoA)还原酶来降低脂质水平,从而降低胆固醇的产生。许多证据表明阿托伐他汀在中风中的有效性,但很少有研究专门研究其神经保护作用及其潜在机制。本文综述了阿托伐他汀在临床前和临床研究中的神经保护作用,并提供了对缺血性卒中中这些可能作用的分子机制的最新讨论。我们希望这篇综述能够帮助读者更好地了解阿托伐他汀在缺血性脑卒中中的作用,并为脑卒中患者的基础研究和新的治疗策略提供更全面的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.40
自引率
6.20%
发文量
118
审稿时长
6-12 weeks
期刊介绍: Journal of Neuropathology & Experimental Neurology is the official journal of the American Association of Neuropathologists, Inc. (AANP). The journal publishes peer-reviewed studies on neuropathology and experimental neuroscience, book reviews, letters, and Association news, covering a broad spectrum of fields in basic neuroscience with an emphasis on human neurological diseases. It is written by and for neuropathologists, neurologists, neurosurgeons, pathologists, psychiatrists, and basic neuroscientists from around the world. Publication has been continuous since 1942.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书